Region Skane Skanes Universitetssjukhus

The trials here

What the 77 trials at this site are about, from their registry records.

Conditions

• Colorectal cancer11 trials
• Alzheimer disease9 trials
• Prostate cancer9 trials
• Haemophilia8 trials
• Type 1 diabetes4 trials
• Chronic kidney disease3 trials
• Stroke3 trials
• Type 2 diabetes3 trials
• ALS (motor neurone disease)2 trials
• Aortic aneurysm2 trials
• Atrial fibrillation2 trials
• Childhood cancers2 trials
• and 18 more

Phase

• Phase 340 trials
• Phase 218 trials
• Phase 410 trials
• Phase 1/23 trials
• Phase 2/33 trials
• Phase 12 trials

Status

• Completed25 trials
• Active, not recruiting22 trials
• Recruiting18 trials
• Not yet recruiting10 trials
• Suspended2 trials

Lead sponsor

• Novo Nordisk A/S6 trials
• Region Skane5 trials
• AstraZeneca4 trials
• Uppsala University4 trials
• Boehringer Ingelheim2 trials
• and 42 more

Running trials

• Not yet recruiting

  Phase 3 Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC 6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

  2025-524969-24-00· Phase 3· Revolution Medicines Inc.· Source

• Recruiting

  Comparing Intraoperative Indocyanine Green Fluorescence Imaging With Standard Clinical Assessment for Flap Perfusion in Head and Neck Reconstruction (VISION Trial)

  NCT07635420· Phase 4· Region Skane· Source

• Recruiting

  A study to evaluate the efficacy of oxaliplatin- or gemcitabine-based chemotherapy after allocation by standard criteria or by genetic markers in patients with resected pancreatic carcinoma

  NCT05314998· Phase 3· Universitaetsklinikum Heidelberg AöR· Source

• Not yet recruiting

  COLOVERT – Conversion therapy in colorectal cancer with peritoneal metastases not amenable to upfront cytoreductive surgery and HIPEC: a phase II “pick-the-winner” open-label randomized trial

  2026-526122-41-00· Phase 2· Uppsala University Hospital· Source

• Recruiting

  Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease

  NCT07318610· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  Anti-B-cell therapy in RA-ILD

  2025-524872-51-00· Phase 4· Vaestra Goetalandsregionen· Source

• Recruiting

  Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis

  NCT07325292· Phase 3· Sanofi· Source

• Not yet recruiting

  Next generation StaR-TREC

  2025-522955-25-00· Phase 4· Vaestra Goetalandsregionen· Source

• Not yet recruiting

  Contrast Strategy In Fenestrated EndoVascular Aneurysm Repair Randomized Control Trial

  2025-521795-58-00· Phase 4· Region Skane· Source

• Recruiting

  A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A

  NCT07220564· Phase 1· Novo Nordisk A/S· Source

• Recruiting

  Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis

  NCT07023835· Phase 2· Zydus Therapeutics Inc.· Source

• Recruiting

  A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

  NCT06926868· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

  NCT06948318· Phase 3· Takeda· Source

• Recruiting

  A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

  NCT06952803· Phase 3· AstraZeneca· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

  NCT06925737· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Thrombolysis in Factor Xa-inhibitors Trial

  NCT06878066· Phase 3· Guri Hagberg· Source

• Active, not recruiting

  A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

  NCT06764485· Phase 3· Celgene· Source

• Active, not recruiting

  Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa

  NCT06716814· Phase 3· Swedish Orphan Biovitrum· Source

• Recruiting

  A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

  NCT06722235· Phase 3· Takeda· Source

• Active, not recruiting

  A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa Prophylaxis

  NCT06752850· Phase 4· Swedish Orphan Biovitrum· Source

• Active, not recruiting

  EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

  NCT06531824· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Anti-viral action against Type 1 diabetes autoimmunity GPPAD-05-AVAnT1A

  2023-507348-35-00· Phase 4· Klinikum rechts der Isar der TU Muenchen AöR· Source

• Active, not recruiting

  Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease

  NCT06268886· Phase 2· Bristol-Myers Squibb· Source

• Recruiting

  Study to assess the safety and efficacy of the SpectraCure P18 System

  2022-502285-24-00· Phase 1/2· SpectraCure AB (publ)· Source

• Active, not recruiting

  Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

  NCT06141486· Phase 3· Sanofi· Source

• Enrolling by invitation

  Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222)

  NCT05962398· Phase 2/3· CSL Behring· Source

• Recruiting

  Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

  NCT05855200· Phase 3· GlaxoSmithKline· Source

• Recruiting

  Tranexamic acid for hyperacute spontaneous IntraCerebral Haemorrhage (TICH-3)

  2022-500587-35-01· Phase 3· University Of Nottingham· Source

• Recruiting

  A Randomized Trial of Trastuzumab Deruxtecan and Biology-Driven Selection of Neoadjuvant Treatment for HER2-positive Breast Cancer

  NCT05900206· Phase 2· Karolinska University Hospital· Source

• Active, not recruiting

  A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies

  NCT05794906· Phase 3· Bayer· Source

• Recruiting

  Use of GnRHa During Chemotherapy for Fertility Protection

  NCT05328258· Phase 3· Kenny Rodriguez-Wallberg· Source

• Recruiting

  SACK

  2022-501600-10-00· Phase 3· Karolinska University Hospital· Source

• Active, not recruiting

  A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

  NCT05629585· Phase 3· AstraZeneca· Source

• Recruiting

  Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome

  NCT04920149· Phase 2· Ann-Sofie Backman· Source

• Active, not recruiting

  Mesenchymal Stromal Cells to Treat Type 1 Diabetes in Children and Adolescents

  NCT05061030· Phase 1/2· Uppsala University Hospital· Source

• Active, not recruiting

  Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

  NCT04862663· Phase 3· AstraZeneca· Source

• Recruiting

  Efficacy of Hyperthermic Intraperitoneal Chemotherapy

  NCT04861558· Phase 3· Uppsala University· Source

• Active, not recruiting

  Adjuvant instillations in intermediate risk NMIBC: A Study comparIng Gemcitabine and MitomYciN (SIGYN-trial)

  2023-504945-30-00· Phase 3· Region Skane· Source

• Not yet recruiting

  Early intervention and recovery of sexual function in men and women after treatment of rectal cancer–a randomized placebo-controlled study with tadalafil

  2023-504592-24-00· Phase 2· Karolinska Institutet· Source

• Active, not recruiting

  A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer

  NCT04557059· Phase 3· Janssen Pharmaceutica N.V., Belgium· Source

• Recruiting

  Treatment of Hemophilia A Patients With FVIII Inhibitors

  NCT04023019· Phase 4· Emory University· Source

• Recruiting

  Does metformin reduce growth rate of small abdominal aortic aneurysms?

  NCT04224051· Phase 2· Uppsala University· Source

• Active, not recruiting

  Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors

  NCT04082429· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease

  NCT03887455· Phase 3· Eisai Inc.· Source

• Recruiting

  Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction

  NCT02901184· Phase 3· Uppsala University· Source

• Active, not recruiting

  Can we Save the Rectum by Watchful Waiting or TransAnal Surgery Following (Chemo)Radiotherapy Versus Total Mesorectal Excision for Early REctal Cancer?

  NCT02945566· Phase 2/3· University of Birmingham· Source

• Recruiting

  Stopping anti-TNF treatment in Crohn's and Colitis patients in remission

  2024-513299-17-00· Phase 4· Region Skane· Source

• Active, not recruiting

  A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

  NCT02960022· Phase 2· Astellas Pharma Global Development, Inc.· Source

• Active, not recruiting

  Adjuvant Low Dose Aspirin in Colorectal Cancer

  NCT02647099· Phase 3· Anna Martling· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer5 recruiting
• Prostate cancer3 recruiting
• Aortic aneurysm2 recruiting
• Atrial fibrillation2 recruiting
• Haemophilia2 recruiting
• Pancreatic cancer2 recruiting
• Stroke2 recruiting
• ALS (motor neurone disease)1 recruiting
• Childhood cancers1 recruiting
• Chronic kidney disease1 recruiting
• Crohn's disease1 recruiting
• Head and neck cancer1 recruiting
• High blood pressure1 recruiting
• Immune thrombocytopenia (ITP)1 recruiting
• Metastatic breast cancer1 recruiting
• Multiple sclerosis1 recruiting
• Peripheral artery disease1 recruiting
• Rheumatoid arthritis1 recruiting
• Sarcoma1 recruiting
• Type 1 diabetes1 recruiting
• Type 2 diabetes1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Completed

  A clinical trial to learn about the effects of VHB937 in people with Alzheimer's disease

  2024-516966-12-00· Phase 2· Novartis Pharma AG· Source

• Completed

  GSK4527226 Open-label Extension Study in Patients with Early Alzheimer's Disease.

  2025-521107-42-00· Phase 2· Glaxosmithkline Research & Development Limited· Source

• Active, not recruiting

  A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease

  NCT06544616· Phase 2· Janssen Pharmaceutica N.V., Belgium· Source

• Recruiting

  Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

  NCT06282575· Phase 3· Jazz Pharmaceuticals· Source

• Completed

  A Study to evaluate the safety and feasibility of Diamyd® in individuals at risk for Type 1 diabetes

  2024-513350-30-00· Phase 2· Diamyd Medical AB· Source

• Completed

  EFFICACY AND SAFETY OF GSK4527226 [AL101] IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE

  NCT06079190· Phase 2· Glaxosmithkline Research & Development Limited· Source

• Completed

  Effect of orlistat on LIVER fat content in obese subjects with NAFLD and High concEntrAtion of pLasma proneurotensin THrough inhibition of neurotensin secretion and action

  2022-500366-10-00· Phase 2· Region Skane· Source

• Active, not recruiting

  Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

  NCT06120491· Phase 3· AstraZeneca· Source

• Completed

  A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

  NCT06065540· Phase 3· Novo Nordisk A/S· Source

• Completed

  A 24-month study evaluating physical activity and joint health in patients 12 years and older, with severe haemophilia A treated once weekly with efanesoctocog alfa.

  2022-500275-31-00· Phase 3· Swedish Orphan Biovitrum AB (publ)· Source

• Active, not recruiting

  Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants

  NCT05469360· Phase 1· Novartis Pharmaceuticals· Source

• Completed

  A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy, Safety, Tolerability, PK, and Biomarker Effects of PTC857 in Adult Subjects With Amyotrophic Lateral Sclerosis (CARDINALS)

  NCT05349721· Phase 2· PTC Therapeutics Inc.· Source

• Completed

  A Study of Relatlimab-nivolumab Fixed-dose Combination versus Regorafenib or TAS-102 in Participants with Later-lines of Metastatic Colorectal Cancer

  NCT05328908· Phase 3· Bristol Myers Squibb International Corporation· Source

• Active, not recruiting

  Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)

  NCT05263934· Phase 3· GlaxoSmithKline· Source

• Completed

  A clinical study to investigate if the investigational drug Diamyd is safe and can preserve insulin production and secretion in adolescents and adults that have recently been diagnosed type 1 diabetes. The safety of Diamyd will also be investigated. Some subjects may receive a placebo drug.

  NCT05018585· Phase 3· Diamyd Medical AB· Source

• Active, not recruiting

  OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosilicate in Heart Failure

  NCT04789239· Phase 2· Michael Fu· Source

• Completed

  ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

  NCT05021835· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

  NCT04777396· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

  NCT04777409· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer

  NCT04486378· Phase 2· BioNTech SE· Source

• Completed

  Observational Study To Assess The Effectiveness and Treatment Adherence Of Tofacitinib of Ulcerative Colitis In Clinical Practice In Sweden

  NCT04338204· Pfizer· Source

• Completed

  SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes

  NCT03982381· Phase 4· Uppsala University· Source

• Completed

  HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients

  NCT03569891· Phase 3· CSL Behring· Source

• Completed

  Beta-blockers to Patients With Chronic Obstructive Pulmonary Disease

  NCT03566667· Phase 4· Ole Frobert, MD, PhD· Source

• Active, not recruiting

  Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

  NCT02861573· Phase 1/2· Merck Sharp & Dohme LLC· Source